Integra LifeSciences Holdings Corporation (IART) Position Trimmed by Bank of New York Mellon Corp

Bank of New York Mellon Corp lowered its position in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 3.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 739,169 shares of the life sciences company’s stock after selling 27,920 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.94% of Integra LifeSciences worth $37,312,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of IART. LS Investment Advisors LLC lifted its stake in Integra LifeSciences by 4.6% in the second quarter. LS Investment Advisors LLC now owns 2,523 shares of the life sciences company’s stock valued at $138,000 after buying an additional 111 shares during the last quarter. Aperio Group LLC lifted its stake in Integra LifeSciences by 16.1% in the second quarter. Aperio Group LLC now owns 20,956 shares of the life sciences company’s stock valued at $1,142,000 after buying an additional 2,906 shares during the last quarter. Strs Ohio increased its holdings in shares of Integra LifeSciences by 60.4% in the second quarter. Strs Ohio now owns 7,700 shares of the life sciences company’s stock valued at $419,000 after purchasing an additional 2,900 shares during the period. Great West Life Assurance Co. Can increased its holdings in shares of Integra LifeSciences by 4.6% in the second quarter. Great West Life Assurance Co. Can now owns 87,125 shares of the life sciences company’s stock valued at $4,746,000 after purchasing an additional 3,823 shares during the period. Finally, CIBC Asset Management Inc acquired a new position in shares of Integra LifeSciences in the second quarter valued at approximately $251,000. Institutional investors own 87.62% of the company’s stock.

A number of research analysts have recently issued reports on IART shares. Zacks Investment Research lowered Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 25th. Royal Bank Of Canada reissued a “sector perform” rating and issued a $50.00 target price (up previously from $48.00) on shares of Integra LifeSciences in a report on Thursday, November 9th. Barclays reaffirmed an “equal weight” rating and set a $53.00 price objective (up previously from $47.00) on shares of Integra LifeSciences in a report on Tuesday, September 12th. Wells Fargo & Company lowered Integra LifeSciences from an “outperform” rating to a “market perform” rating in a report on Sunday, October 29th. Finally, J P Morgan Chase & Co lowered Integra LifeSciences from an “overweight” rating to a “neutral” rating and set a $44.00 price objective on the stock. in a report on Friday, October 27th. Seven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Integra LifeSciences has a consensus rating of “Buy” and an average price target of $53.82.

Shares of Integra LifeSciences Holdings Corporation (IART) opened at $48.08 on Friday. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.49 and a quick ratio of 3.39. Integra LifeSciences Holdings Corporation has a 12-month low of $38.51 and a 12-month high of $56.42. The stock has a market capitalization of $3,748.08, a price-to-earnings ratio of 26.39, a PEG ratio of 2.09 and a beta of 0.65.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Thursday, October 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.47 by ($0.02). Integra LifeSciences had a net margin of 4.52% and a return on equity of 16.35%. The company had revenue of $278.83 million during the quarter, compared to analysts’ expectations of $286.00 million. During the same quarter in the prior year, the company earned $0.93 earnings per share. The firm’s revenue was up 11.4% compared to the same quarter last year. sell-side analysts anticipate that Integra LifeSciences Holdings Corporation will post 1.85 EPS for the current fiscal year.

In other news, Director Barbara B. Hill acquired 10,768 shares of the business’s stock in a transaction dated Tuesday, October 31st. The shares were bought at an average cost of $46.66 per share, for a total transaction of $502,434.88. Following the acquisition, the director now directly owns 55,540 shares in the company, valued at approximately $2,591,496.40. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, VP Richard D. Gorelick sold 1,500 shares of the firm’s stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $47.19, for a total value of $70,785.00. Following the completion of the transaction, the vice president now owns 21,665 shares in the company, valued at $1,022,371.35. The disclosure for this sale can be found here. Corporate insiders own 21.50% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://ledgergazette.com/2017/12/08/integra-lifesciences-holdings-corporation-iart-position-trimmed-by-bank-of-new-york-mellon-corp.html.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corporation (NASDAQ:IART).

Institutional Ownership by Quarter for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply